Less than a year after the first wave of COVID-19 was reported in Wuhan, China, the international scientific community launched its first preventive SARS-Cov-2 (COVID-19) vaccines. In December 2020, the United Kingdom began administering index doses of this vaccine, followed by the worldwide approval and implementation of several other candidate vaccines. There have been growing concerns about the potential for an unequal distribution of vaccines around the world, which could have a negative impact on global health security and health outcomes, as a result of this innovation. Phase 2 of CTAP’s COVID-19 Vaccine Evolution and Hesitancy Study sought to outline Ghana’s COVID-19 vaccine evolution, hesitancy, current vaccination levels and distribution, adequacy and related emerging issues in order to inform civil society advocacy for vaccine equity in Ghana.